You are here:

ibrutinib (Imbruvica)

Advice

in the absence of a submission from the holder of the marketing authorisation:

ibrutinib (Imbruvica®) is not recommended for use within NHS Scotland.

Indication under review: As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: ibrutinib (Imbruvica)
SMC Drug ID: 1289/17
Manufacturer: Janssen-Cilag Ltd
Indication: As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 November 2017

Back